The BenevolentAI Award is back! Presented through a competition for AMRC members, the Award offers a selected charity AI-driven research and development support from BenevolentAI.
BenevolentAI, is an artificial intelligence company developing and applying advanced technologies to transform the way drugs are designed, developed, tested and brought to market. The company has developed the ‘Benevolent Platform’ an end-to-end computational and experimental platform for drug discovery that’s spans data ingestion to clinical development
Last year, the BenevolentAI award was won by Parkinson’s UK and the Cure Parkinson’s Trust. The project aimed to identify available medicines that can be re-purposed to address Parkinson’s disease as well as brand-new drugs.
BenevolentAI and AMRC are running the Award once again to help charities accelerate their medical research by using artificial intelligence.
The BenevolentAI Award will offer the winning application access to the Benevolent Platform to solve specific research challenges the selected charity is facing. BenevolentAI will apply its technology to the given charity’s area of interest to interrogate the vast array of available biomedical data sources and generate new ideas and thinking. It will also give access to BenevolentAI’s scientific expertise, resources and network.
The award is of an ‘in kind’ nature and aimed at solving a specific challenge the charity is facing, for example:
Essentially, the award offers the potential to drive forward a charity’s scientific mission to create better understanding of disease, the relevant research landscape and develop new treatments and therapies.
06 December 2018
Formal launch of Award to AMRC members and the media
Dec 2018 – Mar 2019
AMRC member Award education events (explaining the technology and demonstrating its potential for medical charity R&D activities)
15 March 2019
Deadline for BenevolentAI Award submissions
BenevolentAI and AMRC initial submission selection process
Applicants informed outcome of successful final selection for judging
Awards panel judging
An Award judging panel consisting of Jackie Hunter, CEO Clinical Programmes and Strategic Relationships at BenevolentAI, Aisling Burnand, CEO of the AMRC, Professor Yi-Ke Guo, Professor of Computing Science at Imperial College London, a member of industry and a patient representative will assess applications and choose a winner which will be announced in May 2019.
BenevolentAI, founded in 2013, is an AI company developing and applying advanced technologies to accelerate the journey from data to medicine. The company combines the power of computational medicine and advanced AI with the principles of open systems and cloud computing to transform the way drugs are designed, developed, tested and brought to market.
BenevolentAI seeks to improve patient’s lives by applying technology designed to lower drug development costs, decrease failure rates and increasing the speed at which medicines are generated. BenevolentAI’s approach to this is to integrate technology across the entire medicinal R&D process (rather than fragments of it) and by doing so solve fundamental innovation roadblocks such as the ability to ingest large data sets, meaningful reasoning on those data sets, validation of ideas from those data sets and the rapid experimentation of those ideas.
The company has developed the ‘Benevolent Platformä’, the world’s only end-to-end computational and experimental platform for drug discovery which is used by BenevolentAI scientists to find new ways to treat disease and personalise drugs to patients. The Benevolent Platformä is continuously ingesting and analysing unstructured and structured biomedical information, from academic papers to compound databases, to clinical trials, to scientific patents. This information is combined with deep learning to create the world’s leading bioscience knowledge graph coupled with an automated platform for hypothesis generation and validation followed by the design, refinement and synthesis of molecules.
BenevolentAI is HQ’d in London with a research facility in Cambridge (UK) and further offices in New York and Belgium. BenevolentAI has active R&D drug programmes from discovery to PhaseIIb in disease areas such as ALS, Parkinson’s, Ulcerative Colitis and Sarcopenia. As well as entering license agreements with pharmaceutical companies, BenevolentAI works with charities and NGOs including Life Arc (formerly MRC Technology), Queen Mary University, Parkinson’s UK, the Cure Parkinson’s Trust, Action Against AMD and SITraN, the Sheffield Institute for Translational Neuroscience.
If you require any help during the application process, please contact Carol Bewick or Andy Clempson at AMRC: [email protected]; [email protected].
Please do not approach members of the awards panel directly. In doing so, you are risking their impartiality on your application, and it may be withdrawn.